2F16

Crystal structure of the yeast 20S proteasome in complex with bortezomib

Summary for 2F16

• Entry DOI: 10.2210/pdb2f16/pdb
• Related: 1PMA 1RYP
• Descriptor: Proteasome component Y7, Proteasome component C11, Proteasome component PRE2, ... (16 entities in total)
• Functional Keywords: beta-sandwich flanked by helices, complex structure covalently bound to the synthetic inihibtor bortezomib, hydrolase
• Biological source: Saccharomyces cerevisiae (baker's yeast); More
• Cellular location: Cytoplasm: P23639 P22141 P30656 P23724 P30657 P38624 P23638 P40303 P32379 P40302 P21242 P21243 P25043 P25451
• Total number of polymer chains: 28
• Total formula weight: 706511.66

Authors

Groll, M. (deposition date: 2005-11-14, release date: 2006-03-21, Last modification date: 2024-10-30)

Primary citation

Groll, M.,Berkers, C.R.,Ploegh, H.L.,Ovaa, H.
Crystal Structure of the Boronic Acid-Based Proteasome Inhibitor Bortezomib in Complex with the Yeast 20S Proteasome.
Structure, 14:451-456, 2006

PubMed Abstract: The dipeptide boronic acid bortezomib, also termed VELCADE, is a proteasome inhibitor now in use for the treatment of multiple myeloma, and its use for the treatment of other malignancies is being explored. We determined the crystal structure of the yeast 20S proteasome in complex with bortezomib to establish the specificity and binding mode of bortezomib to the proteasome's different catalytically active sites. This structure should enable the rational design of new boronic acid derivatives with improved affinities and specificities for individual active subunits.

PubMed: 16531229
DOI: 10.1016/j.str.2005.11.019

Experimental method

X-RAY DIFFRACTION (2.8 Å)